Inpatient eligibility for Ronapreve treatment has now changed

November 18, 2021

Patients who are hospitalised for the management of COVID-19 and hospitalised patients with incidental/nosocomial COVID-19 can receive treatment. There are different doses for each cohort of patients, details can be found in the “nMABs in hospitalised patients” pathway or by clicking here.

Note: Patients in ED and AMU should all be tested for anti-spike (anti-S) antibodies against SARS-CoV-2. This can be done as an add-on test.

The treatment has been developed from the results of the RECOVERY trial. nMABs is proven to reduce the potential risk of serious illness and reduces the length of time patients spend in hospital receiving treatment for the management of COVID-19.

All pathways can be found on the Covid Clinical Guidance page.